摘要
非酒精性脂肪性肝炎(NASH)是一种以肝脂肪变性、炎性细胞浸润或伴有间质纤维增生为主要病理特征的慢性肝脏疾病,是肝纤维化、肝硬化和肝癌的重要风险阶段。NOD样受体蛋白3(NLRP3)炎症小体是先天免疫系统的核心,其异常激活与NASH的发生发展密切相关,涉及炎症反应与氧化应激等多个环节。大量研究表明,中药活性成分及中药复方可通过调节NLRP3炎症小体达到改善氧化应激、调节脂质代谢和减轻肝脏炎症的作用。临床上运用中医药治疗NASH已取得良好疗效,而炎症小体是部分中药改善NASH的关键途径或靶点之一。本文综述NLRP3炎症小体在NASH中的作用机制及中医药干预NLRP3炎症小体的研究进展,以期为NASH的中医药临床治疗提供思路,并为中药新药研发提供参考靶点及研究方向。
Nonalcoholic steatohepatitis(NASH)is a chronic liver disease with the main pathological features of hepatic steatosis,inflammatory cell infiltration,and interstitial fibroplasia,and it is an important risk factor for liver fibrosis,liver cirrhosis,and hepatocellular carcinoma.NOD-like receptor protein 3(NLRP3)inflammasome is the core of innate immunity,and the abnormal activation of NLRP3 inflammasome is closely associated with the development and progression of NASH,which involves multiple links such as inflammatory response and oxidative stress.A large number of studies have shown that the active ingredients of traditional Chinese medicine(TCM)and TCM compound prescriptions can improve oxidative stress,regulate lipid metabolism,and alleviate liver inflammation by regulating NLRP3 inflammasome.TCM treatment applied in clinical practice has achieved a good therapeutic effect,while inflammasome is one of the key pathways or targets for TCM in improving NASH.This article reviews the mechanism of action of NLRP3 inflammasome in NASH and the research advances in TCM intervention of NLRP3 inflammasome,in order to provide ideas for the clinical TCM treatment of NASH,as well as reference targets and research directions for the research and development of new TCM drugs.
作者
张金雪
刘俊宏
陈佳乐
王丹
苏李宁
陈雅洁
赖学倩
王淼蕾
李亚静
ZHANG Jinxue;LIU Junhong;CHEN Jiale;WANG Dan;SU Lining;CHEN Yajie;LAI Xueqian;WANG Miaolei;LI Yajing(School of Integrated Traditional Chinese and Western Medicine,Gansu University of Chinese Medicine,Lanzhou 730000,China;Department of Spleen and Stomach Diseases,The Affiliated Hospital of Gansu University of Chinese Medicine,Lanzhou 730000,China;Pediatric Emergency Center Branch II,Gansu Provincial Central Hospital,Lanzhou 730000,China)
出处
《临床肝胆病杂志》
北大核心
2025年第11期2365-2371,共7页
Journal of Clinical Hepatology
基金
2022年青年岐黄学者基金项目(国中医药人教函〔2022〕256号)
甘肃省中医药管理局重点项目(GZKZ-2021-6)
2022年甘肃省科技厅重点研发计划(22YFTFA100)
甘肃省科学技术厅创新基地和人才计划(21JR7RA682)
2022年省级重点人才项目和陇原青年创新创业人才项目(2022RCXM020)。
